Why does apheresis require acid‑citrate‑dextrose (ACD) anticoagulation, and why is calcium replacement more aggressive during continuous renal replacement therapy (CRRT) when citrate is used?

Why Apheresis Requires ACD and Why CRRT Citrate Demands More Aggressive Calcium Replacement

Apheresis requires ACD because citrate chelates calcium to prevent blood clotting in the extracorporeal circuit, while CRRT with citrate anticoagulation requires more aggressive calcium replacement because citrate is continuously infused at higher rates over prolonged periods (often 24+ hours), creating sustained systemic hypocalcemia that demands intensive monitoring and replacement to prevent life-threatening complications.

Mechanism of Citrate Anticoagulation

Citrate works by chelating free ionized calcium, making it unavailable to the coagulation cascade 1. This is the fundamental mechanism for both apheresis and CRRT applications 1.

Why Citrate is Preferred for Apheresis

• Safety profile: Citrate is preferred over heparin for the majority of apheresis procedures because it provides effective anticoagulation without systemic bleeding risks 2
• Regional effect: The anticoagulation remains confined to the extracorporeal circuit
• Short duration: Apheresis procedures typically last 2-4 hours, limiting total citrate exposure 3

The Critical Difference: CRRT vs Apheresis

Volume and Duration of Citrate Exposure

The key distinction is the magnitude and duration of citrate administration:

Apheresis:

• Short procedures (2-4 hours)
• Limited total ACD-A volume
• Citrate-related complications are primarily mild dysesthesias 2
• Hypocalcemia develops in 23% of patients but rarely drops below 2.8 mg/dL 4

CRRT with Regional Citrate Anticoagulation:

• Continuous infusion for 24-72+ hours 5, 4
• Citrate doses of 2.5-5.0 mmol/L of blood flow 6, 5
• Target post-filter ionized calcium of 0.25-0.45 mmol/L 7
• Sustained systemic citrate load requiring metabolism through the Krebs cycle 5

Why Calcium Replacement is More Aggressive in CRRT

The intensity of calcium replacement during CRRT is driven by four factors:

1. Continuous citrate infusion: Unlike apheresis's brief exposure, CRRT delivers citrate continuously for days, creating persistent calcium chelation 5, 8

2. Higher total citrate load: Even with lower citrate concentrations (2.5 mmol/L), the cumulative exposure over 24-72 hours far exceeds apheresis 6

3. Risk of citrate accumulation: In critically ill patients, especially those with liver dysfunction, citrate may not be fully metabolized, leading to citrate toxicity with severe metabolic derangements including metabolic alkalosis, hypernatremia, and profound hypocalcemia 5, 4, 8

4. Life-threatening complications: Systemic hypocalcemia during CRRT can cause cardiac arrhythmias, seizures, and tetany—not just mild paresthesias 2, 8

Clinical Management Algorithm

CRRT Calcium Replacement Protocol

Target systemic ionized calcium: 1.01-1.20 mmol/L 6

• Continuous IV calcium infusion (typically calcium gluconate or calcium chloride) post-filter 4, 6
• Frequent monitoring: Check ionized calcium every 4-6 hours initially, then every 6-12 hours once stable 4, 8
• Titrate calcium infusion by protocol to maintain systemic levels 6
• Monitor for citrate accumulation: Watch for widening anion gap, metabolic alkalosis, rising total calcium with falling ionized calcium 4, 9

Apheresis Calcium Management

• Oral calcium supplementation often sufficient 3
• IV calcium only for symptomatic hypocalcemia or ionized calcium <3.6 mg/dL 4
• Less intensive monitoring due to shorter procedure duration 2

Critical Pitfalls to Avoid

In CRRT:

• Never assume adequate citrate metabolism in liver dysfunction—citrate accumulation causes total hypercalcemia with ionized hypocalcemia, a dangerous combination 9
• Don't under-replace calcium: Inadequate replacement risks cardiac arrest and seizures 8
• Monitor the total-to-ionized calcium ratio: A ratio >2.5 suggests citrate accumulation 9

In Apheresis:

• Higher ACD-A volumes and older age increase risk of electrolyte disturbances 3
• Watch for hypokalemia: Two-thirds of donors develop biochemical hypokalemia post-apheresis 3

Evidence Quality Note

The FDA drug label 1 confirms citrate's mechanism, while recent research 6, 5 demonstrates that even lower citrate doses (2.5 mmol/L) in CRRT require intensive calcium management due to continuous exposure. The 2026 guideline 10 notes that when CRRT runs with ECMO, heparin from ECMO anticoagulates both circuits, eliminating the need for additional citrate—highlighting that citrate's use is specifically for anticoagulation when systemic heparin is contraindicated.